OMC Financial Services LTD lowered its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 4.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,940 shares of the company’s stock after selling 200 shares during the quarter. OMC Financial Services LTD’s holdings in Zoetis were worth $642,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Darwin Wealth Management LLC acquired a new position in shares of Zoetis during the third quarter valued at about $31,000. First Personal Financial Services bought a new position in Zoetis in the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP acquired a new position in Zoetis during the 3rd quarter valued at about $33,000. Dunhill Financial LLC increased its holdings in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Fortitude Family Office LLC raised its stake in shares of Zoetis by 1,387.5% in the third quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after purchasing an additional 222 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.
Zoetis Stock Down 1.6 %
Zoetis stock opened at $171.37 on Monday. The firm has a 50 day moving average price of $169.26 and a 200-day moving average price of $179.22. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company has a market capitalization of $77.32 billion, a P/E ratio of 32.21, a P/E/G ratio of 2.77 and a beta of 0.90.
Zoetis Dividend Announcement
Wall Street Analysts Forecast Growth
ZTS has been the topic of several analyst reports. UBS Group initiated coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price on the stock. Leerink Partners assumed coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective on the stock. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Stifel Nicolaus cut their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, Morgan Stanley decreased their price objective on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $215.00.
About Zoetis
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Articles
- Five stocks we like better than Zoetis
- Best Stocks Under $10.00
- 3 Volatility ETFs to Help You Profit from Market Chaos
- How to Read Stock Charts for Beginners
- Lam Research: Is a NAND Upgrade Cycle the Next Growth Catalyst?
- Comparing and Trading High PE Ratio Stocks
- Chipotle’s Slip: A Short-Term Dip or Long-Term Opportunity?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.